NOMURA HOLDINGS INC-SPON ADR (NMR)
US65535H2085 - ADR
Overall NMR gets a fundamental rating of 4 out of 10. We evaluated NMR against 220 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR has a decent growth rate and is not valued too expensively. Finally NMR also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
In the past year NMR has reported a negative cash flow from operations.
NMR had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
NMR has a worse Return On Assets (0.48%) than 74.65% of its industry peers.
With a Return On Equity value of 8.32%, NMR perfoms like the industry average, outperforming 49.77% of the companies in the same industry.
The Return On Invested Capital of NMR (0.49%) is worse than 79.72% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.00%.
The last Return On Invested Capital (0.49%) for NMR is above the 3 year average (0.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROIC | 0.49% |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
1.3 Margins
The Profit Margin of NMR (5.83%) is worse than 68.20% of its industry peers.
NMR's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 8.63%, NMR is doing worse than 72.35% of the companies in the same industry.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a worse Gross Margin (37.85%) than 69.12% of its industry peers.
NMR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% |
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
2. Health
2.1 Basic Checks
NMR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for NMR has been reduced compared to 5 years ago.
The debt/assets ratio for NMR is higher compared to a year ago.
2.2 Solvency
NMR has an Altman-Z score of -0.30. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.30, NMR is not doing good in the industry: 86.64% of the companies in the same industry are doing better.
A Debt/Equity ratio of 11.22 is on the high side and indicates that NMR has dependencies on debt financing.
With a Debt to Equity ratio value of 11.22, NMR is not doing good in the industry: 91.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.23, NMR is doing worse than 82.95% of the companies in the same industry.
NMR has a Quick Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Quick ratio (0.23) than 82.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 108.95%, which is quite impressive.
The Earnings Per Share has been growing slightly by 2.74% on average over the past years.
The Revenue has grown by 36.58% in the past year. This is a very strong growth!
The Revenue has been growing by 17.77% on average over the past years. This is quite good.
EPS 1Y (TTM)108.95%
EPS 3Y2.74%
EPS 5YN/A
EPS Q2Q%189%
Revenue 1Y (TTM)36.58%
Revenue growth 3Y36.99%
Revenue growth 5Y17.77%
Sales Q2Q%25.89%
3.2 Future
The Earnings Per Share is expected to grow by 18.98% on average over the next years. This is quite good.
NMR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.32% yearly.
EPS Next Y56.17%
EPS Next 2Y27.22%
EPS Next 3Y18.98%
EPS Next 5YN/A
Revenue Next Year15.59%
Revenue Next 2Y6.25%
Revenue Next 3Y4.32%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.88, the valuation of NMR can be described as very reasonable.
Based on the Price/Earnings ratio, NMR is valued a bit cheaper than the industry average as 68.66% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of NMR to the average of the S&P500 Index (27.73), we can say NMR is valued rather cheaply.
The Price/Forward Earnings ratio is 9.76, which indicates a very decent valuation of NMR.
Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than 67.28% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. NMR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.88 | ||
| Fwd PE | 9.76 |
4.2 Price Multiples
NMR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NMR is cheaper than 64.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.13 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NMR's earnings are expected to grow with 18.98% in the coming years.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y27.22%
EPS Next 3Y18.98%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 4.12%, which is a nice return.
NMR's Dividend Yield is comparable with the industry average which is at 9.13.
Compared to an average S&P500 Dividend Yield of 2.24, NMR pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 7.29%!
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)7.29%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 25.01% of its income as dividend. This is a sustainable payout ratio.
The dividend of NMR is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.01%
EPS Next 2Y27.22%
EPS Next 3Y18.98%
NOMURA HOLDINGS INC-SPON ADR
NYSE:NMR (12/20/2024, 8:04:01 PM)
After market: 5.73 0 (0%)5.73
+0.04 (+0.7%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners2.09%
Inst Owner Change8.5%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.93B
Analysts68.33
Price Target6.41 (11.87%)
Short Float %0.03%
Short Ratio1.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
Dividend Growth(5Y)7.29%
DP25.01%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.6%
PT rev (3m)0.9%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.27%
EPS NY rev (3m)0.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.88 | ||
| Fwd PE | 9.76 | ||
| P/S | 0.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.8 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | 23.13 |
EPS(TTM)0.58
EY10.12%
EPS(NY)0.59
Fwd EY10.24%
FCF(TTM)-2.76
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS10.16
BVpS7.12
TBVpS7.05
PEG (NY)0.18
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROCE | 1.45% | ||
| ROIC | 0.49% | ||
| ROICexc | 0.54% | ||
| ROICexgc | 0.55% | ||
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% | ||
| FCFM | N/A |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
ROICexc(3y)0.34%
ROICexc(5y)0.37%
ROICexgc(3y)0.34%
ROICexgc(5y)0.38%
ROCE(3y)0.89%
ROCE(5y)1.01%
ROICexcg growth 3Y-3.29%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.32%
ROICexc growth 5YN/A
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
F-Score5
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 78.89 | ||
| Cap/Depr | 1824.53% | ||
| Cap/Sales | 24.27% | ||
| Interest Coverage | 0.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.3 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)580.51%
Cap/Depr(5y)450.89%
Cap/Sales(3y)10.9%
Cap/Sales(5y)10.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.95%
EPS 3Y2.74%
EPS 5YN/A
EPS Q2Q%189%
EPS Next Y56.17%
EPS Next 2Y27.22%
EPS Next 3Y18.98%
EPS Next 5YN/A
Revenue 1Y (TTM)36.58%
Revenue growth 3Y36.99%
Revenue growth 5Y17.77%
Sales Q2Q%25.89%
Revenue Next Year15.59%
Revenue Next 2Y6.25%
Revenue Next 3Y4.32%
Revenue Next 5YN/A
EBIT growth 1Y94.33%
EBIT growth 3Y5.89%
EBIT growth 5YN/A
EBIT Next Year35473.8%
EBIT Next 3Y619.01%
EBIT Next 5YN/A
FCF growth 1Y33.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.55%
OCF growth 3Y-49.33%
OCF growth 5YN/A